N/A
N=16
Effect of an EAA/Whey Composition on Protein Metabolism
Sarcopenia
Bottom Line
View on ClinicalTrials.gov: NCT03502941 ↗Enrolled (actual)
16
Serious AEs
0.0%
Results posted
Nov 2021
Primary outcome: Primary: Protein Anabolism — 3.56; 11.8; 3.02 grams — p=<0.05
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- 6.3 g of EAAs mixture and whey protein isolate (Dietary_supplement); 12.6 g of EAAs mixture and whey protein isolate (Dietary_supplement); 12.6 g of whey protein isolate (Dietary_supplement)
- Age
- Adult · 18+ yrs
- Sex
- All
- Sponsor
- University of Arkansas
- Primary completion
- Apr 2019
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Protein Anabolism |
3.56; 11.8; 3.02 | <0.05 sig |
| PRIMARY Protein Synthesis |
0.024; 0.044; 0.022 | <0.05 sig |
Summary
Sarcopenia, a progressive loss of muscle mass, strength and function, is an inevitable natural process of aging. While it may be impossible to completely reverse the progress of sarcopenia, it is well established that intake of dietary protein through essential amino acids (EAAs) and whey protein increases anabolic response. The current study will test if a specially formulated mixture of EAAs and whey protein can maximally stimulate anabolic responses at the levels of whole body and muscle compared to whey protein alone.
Eligibility Criteria
Inclusion Criteria
- BMI between 20 and 30 kg/m^2
Exclusion Criteria
- Current diagnosis of diabetes
- History of malignancy in the 6 months prior to enrollment
- Weight reduction surgery
- Chronic inflammatory (Lupus, HIV/AIDS)
- Currently pregnant females
- Unable to eat dairy protein
- Unable to stop eating protein or Amino Acid (AA) supplements during the participation
- Regular resistance training (> once per week)
- Concomitant use of corticosteroids (ingestion, injection or transdermal)
- Subjects who cannot safely stop using aspirin for 7 days prior to muscle biopsies
- Hemoglobin less than 9.5 g/dL, and platelets less than 150,000 at the screening visit
- Any other disease or condition placing the subject at increased risk of harm if they were to participate, at the discretion of the study physician
Data sourced from ClinicalTrials.gov (NCT03502941). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.